US EditionUK and India rush to secure trade deal after Trump tariffs
- India is negotiating a trade deal with the UK to exempt pharmaceuticals from tariffs, according to Finance Minister Nirmala Sitharaman.
- India's pharmaceutical sector is under threat due to tariffs affecting its $10 billion drug exports, as firms depend heavily on the U.S. Market.
- U.S. President Donald Trump announced a 90-day pause on higher tariffs, increasing the urgency for countries like India and the UK to secure favorable deals.
- India's reliance on China for active pharmaceutical ingredients presents a vulnerability that could worsen with tariffs, affecting drug access worldwide.
39 Articles
39 Articles
White House insider says tariffs for UK are 'favourable'
President Trump’s counter terror aide Sebastian Gorka has told GB News he finds Britain’s response to tariffs imposed by his administration “bemusing”.Speaking to Christopher Hope, Gorka said the tariffs are “favourable” when compared to EU neighbours.READ THE FULL STORY
India’s Strategic Ascent in Trump’s Trade Tempest
(Analysis) In a world reshaped by Donald Trump’s trade policies, with tariffs reaching 145% on China and redefining global supply chains, India stands at a pivotal crossroads. The U.S. president’s crusade against China’s economic dominance—now targeting pharmaceuticals and semiconductors—casts a shadow over India’s $10 billion drug exports, yet it also illuminates a path to opportunity. […]
Evening Standard
UK would need ‘extraordinary’ deal to go below 10% tariff, Trump adviser says
Sir Keir Starmer’s Government still hopes an economic deal with America can be reached.
Coverage Details
Bias Distribution
- 47% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
